FOSUN PHARMA

Fosun Pharma

BIO International Conference June 13-16, 2022

Rong Yang, CEO Fosun Pharma USA

Disclaimer

This document has been prepared by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (the "Company") and is for presentation use only. Copying, reproduction or redistribution of this document to any person is strictly prohibited. The information contained in this document has not been independently verified. No representation or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The purpose of this document is not for a complete or full analysis of any financial or trading position or prospect, and any person who will be in possession of this document shall be aware that no reliance should be placed on any content contained herein. The information and opinions contained in this document are subject to change without notice, nor will the document be updated to reflect any developments which may occur after the date of this document. The Company or any of its affiliates, advisors or representatives shall not have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document.

This document contains forward-looking statements that are subject to assumptions, risks and uncertainties. These forward-looking statements are generally expressed in forward-looking expressions, such as expectations, estimation, planning, projections, goals, possibilities, probabilities or so on to reflect the actions that the Company expect to or may take in the future or the results from these actions. You should not place undue reliance on these forward-looking statements. Actual results may differ from these forward-looking statements.

This document is for review only by persons who are (i) a "qualified institutional buyer" ("QIB") as defined under Rule 144A under the U.S. Securities Act of 1933, as amended (the "Securities Act") in the United States; or (ii) outside the United States as defined under Regulation S under the Securities Act. By your acceptance of this presentation, you acknowledge that you satisfy the requirements and conditions set forth in the preceding sentence. The distribution of this document in any jurisdiction may be restricted by laws, and persons into whose possession it comes must inform themselves about, and observe, any such restrictions. Any failure to comply with the restrictions may constitute a violation of the federal securities laws of the United States and the laws of other jurisdictions.

This document is not intended to constitute an offer to, or a solicitation for offer to, sell, purchase or subscribe for any securities nor shall it or any part of it form the basis of or being relied on for any contracts or promises.

NO SECURITIES OF THE COMPANY MAY BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION UNDER THE SECURITIES ACT, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS OF THE UNITED STATES. THE SECURITIES TO BE OFFERED BY THE COMPANY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR ANY STATE SECURITIES LAWS OF THE UNITED STATES. THIS PRESENTATION MATERIAL DOES NOT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF THE SECURITIES ACT.

We are a leading innovation-driven international healthcare group in China

OUR MISSION

Better Health for Families Worldwide

OUR VISION

We strive to be a leading enterprise in the global pharmaceutical and healthcare markets OUR VALUE

Care for LifeImage: Continuous InnovationContinuous InnovationImage: Continuous InnovationPursuit of ExcellenceImage: Continuous InnovationSustainable Partnership

FOSUN PHARMA

FOSUN PHARMA



Partnering with innovative companies is a cornerstone of our growth strategy



• FosunKite established as a Joint Venture with Kite Pharma prior to Gilead acquisition



- Commercializing the first CAR-T Cell Therapy approved in China in 2021 to treat Lymphoma patients
- Built a 10,000 m² GMP manufacturing facility and a 2,000 m² R&D center

BIONTECH • Exclusive rights to develop and commercialize BioNTech mRNA vaccine product targeting COVID-19 in Greater China

FOSUN PHARMA • Fosun to perform local clinical trials, obtain regulatory approval and commercialize COVID-19 mRNA vaccine

Enhancing our Internal innovation with Partnering and Investments

FOSUN PHARMA

In-House R&D	 Established over 10 in-house R&D units based on different technologies
In-Licensing	<text></text>
Investments	 • Exploring innovative technologies through incubation and early-stage investments ・ ・ ・

Strategy: Transform Fosun Pharma USA into a strong & recognized innovative player

Fosun Pharma USA Today

- Headquarters, Princeton, NJ
- Portfolio of Specialty Pharmaceutical Injectables & Ophthalmic generics
- Emphasis on quality and patient access
- Highly experienced US commercial team
- Innovation and R&D focused through partnerships

Our Vision Near-Term

- Become a US-focused innovative specialty pharma company driven by R&D and strategic partnerships
 - **Build a portfolio** of high value branded, innovative products for patients with medical needs
- Be recognized as a partner
 of choice

Open for Business

- Backed by the resources of one of China's strongest Pharma companies
 - Led by a **highly experienced** Business Development team
 - Actively looking for deals whether in-licensing or acquisition
- Late development stage post POC or commercial assets
- Our US-based team is ready for deal-making now

Making it personal, US based high pedigree team ready to work with you for US dealmaking



Pharma USA

Rong Yang

CEO, Fosun

Chief Representative of Fosun Pharma Group in the U.S.

Prior to Fosun Pharma USA

VP, Sales, Specialty VP, Hematology Marketing **GM**, Czech and Slovakia

>18 years US and EU leadership



BAYER

Harvard Business School



Kitty Wu VP, Head of BD and Strategy, Innovative Medicine

Responsible for Innovative Medicines BD and Strategy

Prior to Fosun Pharma USA Sr Director, Strategy & **Pipeline Neuroscience** Genentech & Rare Diseases Strategic planning Roche

>10 years, US leadership

PhD/Postdoc





Saadat VP, BD & Strategic Investments at FUSION

BABSON

SCHOOL

GRADUATE

Responsible for BD and Strategy at FUSION

Prior to Fosun Pharma USA elpis **VP**, BD & Strategy **Director**, Commercial Ş SAREPTA strategy

>10 years, US BD leadership

MBA




Ali Pashazadeh The Blackstone Group UBS Goldman Sachs

Fosun Pharma USA

Transaction Advisors







Mark Mayhew Esteve McKinsey & Company

We are seeking strategic partnerships across many therapeutic areas **FOSUN** PHARMA and modalities

Therapeutic Areas

- Oncology
- Autoimmune/Inflammation
- Metabolic Disease
- Neuroscience
- Rare Disease

Drug Modalities

- Small molecules
- Antibodies, including monoclonal, bispecific and ADC
- Gene Therapy/CAR T cell therapy
- Stem cell therapy
- Others (Oligos, peptides, etc.)

Expanding our pipeline by In-licensing, co-development, JV or acquisition

US Rights

- Late stage (post POC) clinical projects or commercial products
- Full development or co-development
- Full commercialization rights preferred
- Peak sales expectations on the order of US\$100-200m

Global Rights

- Open to all stages of preclinical and/or early clinical projects
- Responsible for full development and commercialization

China Rights

- Programs that have PoC in clinic and beyond (Phase II/III preferred)
- Fosun Pharma licenses in or codevelops the program for China
- Responsible for late-stage development, registration and commercialization in China

Rights for US can be independently negotiated and do not need to be linked to other territories

FOSUN PHARMA 复星医药 持续创新 · 乐享健康

复星医药微信公众平台 www.fosunpharma.com

